bioRxiv Science⌕ Search

Biology subjects

Yi, T.

Publications and source records attributed to Yi, T..

7 recordsLinked to original sources

Two shifts in evolutionary lability underlie independent gains and losses of root-nodule symbiosis in a single clade of plants

Root nodule symbiosis (RNS) allows plants to access atmospheric nitrogen converted into usable forms through a mutualistic relationship with soil bacteria. RNS is a complex trait requiring coordination from both the plant host and the bacterial symbiont, and pinpointing the evolutionary origins of root nodules is critical for understanding the genetic basis of RNS. This endeavor is complicated by data limitations and the intermittent presence of RNS in a single clade of ca. 30,000 species of flowering plants, i.e., the nitrogen-fixing clade (NFC). We developed the most extensive de novo phylogeny for all major lineages of the NFC and an enhanced root nodule trait database to reconstruct the evolution of RNS. Through identification of the evolutionary pathway to RNS gain, we show that shifts among heterogeneous evolutionary rates can explain how a complex trait such as RNS can arise many times across a large phylogeny. Our analysis identifies a two-step process in which an ancestral precursor state gave rise to a more labile state from which RNS was quickly gained at specific points in the NFC. Our rigorous reconstruction of ancestral states illustrates how a two-step pathway could have led to multiple independent gains and losses of RNS, contrary to recent hypotheses invoking just a single gain and numerous losses. RNS may be an example of multi-level convergent evolution, thus requiring a broader phylogenetic and genetic scope for genome-phenome mapping to elucidate mechanisms enabling fully functional RNS.

evolutionary biology↗

Cytocapsular cancer evolution analyses of 311 kinds of cancers

Cancer is a leading cause of human lethality. Cytocapsular tube, a newly discovered cancer cell specific organelle in vivo, plays pleiotropic biological functions and its generation distinguishes incomplete from complete cancer cells. It is essential for complete malignant tumor growth, cancer metastasis, conventional cancer drug pan-resistance, and cancer relapse. However, mechanisms of cytocapsular cancer evolution are still elusive. Here, we investigated cytocapsular cancer evolution in 311 kinds/subtype of cancers, including 265 types/subtypes of solid cancers and 46 types/subtypes of liquid/hematological cancers. We analyzed 9,856 pieces of annotated clinical tissue samples from 9,682 cancer patients in the asymptotic early stage, Stages I-IV, and before, during and after cancer treatments. We discovered that cytocapsular cancer evolution in solid cancers includes: transformation, formation of incomplete cancer cells, transition to complete cancer cells surrounded by cytocapsulae (CC), merging of complete cancer cells by devolution, formation of cytocapsular tubes (CCTs) and complete malignant tumors in superlarge CC. This is followed by generation of CCT networks, cancer metastasis, CCT network-tumor system (CNTS), CCT degradation and decomposition, and spatiotemporal moving CNTS. In addition, cytocapsular cancer evolution related to liquid (hematological) cancers including bone marrow, thymus, lymph nodes, and spleen, mirrors the process in solid cancers, except that cancer cells in the blood only form CCs but not CCTs. In summary, our study established a cytocapsular cancer evolution atlas, which may pave an avenue for the research on therapy of both solid and liquid cancers.

cancer biology↗

Cytocapsulae and cytocapsular tubes are golden targets for precise, effective and efficient cancer diagnosis and therapy in 307 kinds of liquid and solid cancers

Cancer is a leading cause of human lethality worldwide. A cancer cell is not only the cytoplasm and nucleus enclosed in the cell membrane. A malignant tumor is not only a mass of cancer cells. Cancer in a patient is not only isolated tumors distributed in tissues and organs. The comprehensive understanding of the complete structural compartments and their biological functions of cancer cells, malignant tumors and tumor systems in patients in vivo is an indispensable prerequisite for effective drug development and efficient clinical cancer pharmacotherapies. However, there remains an open question for a long time: what are the complete structural compartments of cancer cells, malignant tumors and tumor systems in the patient body? Here, we comprehensively and systematically investigated the complete structural compartments of cancer cells, malignant tumors and cytocapsular tube (CCT) network-tumor system (CNTS) of 307 types/subtypes of cancers in 33 kinds of tissues and organs by biochemistry and molecular biology assays with 9,811 clinical cancer tissue specimens from 9,637 cancer patients and >110,000 immunohistochemistry (IHC) fluorescence staining images. We discovered the complete structural compartments of cancer cells, malignant tumors and CNTSs in 307 kinds of cancers, elucidated mechanisms of cytocapsular growth and CCT elongation, and identified the comprehensive procedures of cancer evolution in patients. This study paves avenues for curing all kinds of cancers.

cancer biology↗

Cytocapsular tube network-tumor system is an integrated physical target for the highly effective and efficient pharmacotherapy of solid cancers

Cancer is a leading cause of human lethality and cancer drug pan-resistant tumor metastasis (cdp-rtm) is a major source of cancer death. The integrated cytocapsular tube (CCT) networktumor system (CNTS) is essential for cancer evolution procedures including cancer cell proliferation, migration and dissemination in CCT networks, new tumor growth in CCT terminals, conventional cancer drug pan-resistance, and tumor relapse. The preclinical screening experimentations with CCTs and networks are necessary prerequisites for the discovery and development of cancer drug candidates for efficient clinical trials, and effective and precise clinical cancer pharmacotherapy. However, it is unknown whether the popularly employed conventional mouse experimentations for preclinical therapeutic development generate CCTs and networks. Here, we comprehensively investigated the cancer cell line derived xenografts (CDX) of 8 kinds of cancer cell lines, and patient cancer cells derived-xenografts (PDX) with 16 kinds of clinical primary and metastatic malignant tumor cells in multiple cancer stages by immunohistochemistry staining assays with CCT marker protein antibodies of anti-CM-01 antibodies. We found that there are no CCTs or CCT networks in all these examined 16 CDX and 22 PDX transplanted tumors. Our data evidenced that the conventional transplantation tumors for preclinical therapeutic development do not engender CCTs or CNTS, which is consistent with and provides an explanation of the poor clinical outcomes of the marketed cancer drugs. This study demonstrated that CCT network-tumor system (CNTS) is an integrated physical target for pharmacotherapy, and that preclinical experimentations engendering CNTS (such as CCT xenograft, CCTX) should be employed for the discovery and development of highly effective and efficient cancer drugs aimed for cure of solid cancers.

cancer biology↗

Cytocapsular tubes and networks function as physical superdefence freeway systems conducting conventional cancer drug pan-resistant tumor metastasis

Cancer drug pan-resistant tumor metastasis (cdp-rtm) is a major source of cancer lethality. Cytocapsular tubes (CCTs) and their networks are physical membrane-enclosed freeway systems for cancer cell dissemination across tissues and organs in vivo. Whether cytocapsular tube superlarge biomembranes function as superdenfence and conduct cdp-rtm is unknown. It is also unknown whether conventional cancer drug development methods, including cancer cell line derived xenograft (CDX) and patient cancer cell derived xenograft (PDX), generate cytocapsular tubes (CCTs). It is also unclear whether xenografts can be created that contain CCTs for efficient cancer drug development. Here, we investigated CCT functions related to cancer drug resistance, CCTs in CDX and PDX and CCT xenograft (CCTX). Using clinical cancer tissues, we discovered that CCTs potently shielded against multiple chemotherapy treatments with diverse conventional cancer drugs. Next, our quantitative analyses show that CCT biomembrane drug barriers significantly increase cancer drug resistance by 6.6-folds to14-folds. We found that conventional CDX and PDX animal models do not generate CCTs in these xenografts. By mimicking in vivo cancer cell environments for cancer patient cancer cell culturing, we have successfully isolated CH-5high/CH-6high subpopulations of patient breast cancer cells and pancreas cancer cells that are propertied with cytocapsular tube generation capacities and engender large quantities of CCTs in mouse xenografts. Biochemical and immunohistochemistry analyses demonstrated that CCTs in these xenografts are similar to those in clinical cancer tissues. In summary, our research has identified that CCTs and networks function as physical superdefence freeway systems conducting conventional cancer drug pan-resistant tumor metastasis, and developed a CCTX platform for highly efficient cancer drug development, which pave avenues for more efficient development of effective and precise cancer drugs for tumor cure at both personal and broad-spectrum levels.

cancer biology↗

Cancer Metastases of 202 Kinds of Cancers via Cytocapsular Tubes

BACKGROUNDCancer metastasis is the primary source of solid cancer lethality, but the underlying mechanisms have essentially remained elusive. Recently, we found that cytocapsular tubes, a newly discovered organelle of mammalian cells, conduct cell translocation, suggesting an efficient pathway for cancer cell metastases. METHODSWe performed immunohistochemistry staining and fluorescence microscope imaging analyses of 6 kinds of normal organs (n=14 patients), 38 subtypes of benign tumors (n= 126 patients), and 8,061 clinical solid cancer tissue samples (covering 202 types and subtypes of cancers, and including cancers, paracancer tissues and metastatic cancers) taken from 7,125 cancer patients. These solid cancers cover 30 types of organs. We characterized cytocapsular tubes (CTs), cell migration in CTs, and CT quantity, density, network, superstructures and lifecycle in clinical samples of normal tissues, benign tumors, cancers, paracancer tissues, and metastatic cancers. RESULTSThere is no cytocapsular tubes (CTs) in normal organ tissues. Among the 126 benign tumor samples (covering 38 subtypes) from 126 patients, 86.6% do not have CTs and the other 13.4% show benign-to-malignancy transitions with CTs. Of the 8,061 solid cancer tissue and paracancer samples from 7,125 patients, 100% of cancers (including carcinomas in situ), 100% of paracancer tissues, and 100% of metastatic cancer tissues/organs, harbor large quantities (from thousands to hundreds of thousands) of CTs with many cancer cells in migration inside. CONCLUSIONCytocapsular tubes and networks provide membrane-enclosed physical freeway systems for clinical cancer cell metastasis to neighboring and far-distance tissues and organs.

cancer biology↗

Novel Model of Reversible Vestibular Syndrom Induced by Optogenetic Stimulation

Glutamatergic and GABAergic neurons represent the neural components of the medial vestibular nuclei. We assessed the functional role of glutamatergic and GABAergic neuronal pathways arising from the vestibular nuclei (VN) in the maintenance of gait and balance by optogenetically stimulating the VN in VGluT2-cre and GAD2-cre mice. We demonstrate that glutamatergic, but not GABAergic VN neuronal subpopulation is responsible for immediate and strong posturo-locomotor deficits, comparable to unilateral vestibular deafferentation models. During optogenetic stimulation, the support surface dramatically increased in VNVGluT2+ mice, and rapidly fell back to baseline after stimulation, whilst it remained unchanged during similar stimulation of VNGAD2+ mice. This effect persisted when vestibular compensation was removed. Posturo-locomotor alterations evoked in VNVGluT2+ animals were still present immediately after stimulation, while they disappeared 1h later. Overall, these results indicate a fundamental role for VNVGluT2+ neurons in balance and posturo-locomotor functions, but not for VNGAD2+ neurons, in this specific context. This new optogenetic approach will be useful to characterize the role of the different VN neuronal populations involved in vestibular physiology and pathophysiology. HighlightsO_LIFor the first time, Vestibular nuclei were optogenetically stimulated in free-moving animals, to asses for glutamatergic and GABAergic neurons functions in posturo-locomotor behaviors. C_LIO_LIBrief optogenetic activation of VNVGluT2+, but not VNGAD2+, induced immediate and strong postural deficit. C_LIO_LIStimulation of VNVGluT2+ neurons provoked an imbalance with continuous effect on locomotion for a short period of time after stimulation. C_LIO_LIThese results are comparable to the classical vestibular deafferentation models during their peak of deficit, and set optogenetic stimulation as a new model to study vestibular deficits. C_LI

neuroscience↗